V Mandilaras1, N Bouganim1, J Spayne2, R Dent3, A Arnaout4, J F Boileau5, M Brackstone6, S Meterissian7, M Clemons8. 1. Department of Medical Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC. 2. Division of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON. 3. Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON. 4. Ottawa Hospital Cancer Centre and Ottawa Hospital Research Institute, Ottawa, ON. 5. Department of Oncology, Jewish General Hospital and Segal Cancer Centre, Montreal, QC. 6. London Regional Cancer Program, Division of General Surgery/Surgical Oncology, London, ON. 7. Department of Surgical Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC. 8. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON.
Abstract
BACKGROUND: In cases of locally advanced breast cancer (labc), preoperative ("neoadjuvant") therapy was traditionally reserved to render the patient operable. More recently, neoadjuvant therapy, particularly chemotherapy, is being used in patients with operable disease to increase the opportunity for breast conservation. Despite the increasing use of preoperative chemotherapy, rates of pathologic complete response, a surrogate marker for disease-free survival, remain modest in patients with locally advanced disease and particularly so when the tumour is estrogen or progesterone receptor-positive and her2-negative. A new paradigm for labc patients is needed. In other solid tumours (for example, rectal, esophageal, and lung cancers), concurrent chemoradiotherapy (ccrt) is routinely used in neoadjuvant and adjuvant treatment protocols alike. RESULTS: The literature suggests that ccrt in labc patients with inoperable disease is associated with response rates higher than would be anticipated with systemic therapy alone. CONCLUSIONS: Ongoing trials in this field are eagerly awaited to determine if ccrt should become the new paradigm.
BACKGROUND: In cases of locally advanced breast cancer (labc), preoperative ("neoadjuvant") therapy was traditionally reserved to render the patient operable. More recently, neoadjuvant therapy, particularly chemotherapy, is being used in patients with operable disease to increase the opportunity for breast conservation. Despite the increasing use of preoperative chemotherapy, rates of pathologic complete response, a surrogate marker for disease-free survival, remain modest in patients with locally advanced disease and particularly so when the tumour is estrogen or progesterone receptor-positive and her2-negative. A new paradigm for labc patients is needed. In other solid tumours (for example, rectal, esophageal, and lung cancers), concurrent chemoradiotherapy (ccrt) is routinely used in neoadjuvant and adjuvant treatment protocols alike. RESULTS: The literature suggests that ccrt in labc patients with inoperable disease is associated with response rates higher than would be anticipated with systemic therapy alone. CONCLUSIONS: Ongoing trials in this field are eagerly awaited to determine if ccrt should become the new paradigm.
Entities:
Keywords:
Breast cancer; concurrent chemoradiotherapy; locally advanced disease; neoadjuvant therapy
Authors: Neil Isaac; Tony Panzarella; Anthea Lau; Catherine Mayers; Peter Kirkbride; Ian F Tannock; Katherine A Vallis Journal: Cancer Date: 2002-08-15 Impact factor: 6.860
Authors: Johnny Kao; Suzanne D Conzen; Nora T Jaskowiak; David H Song; Wendy Recant; Rachana Singh; Gregory A Masters; Gini F Fleming; Ruth Heimann Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: Aman U Buzdar; Vicente Valero; Nuhad K Ibrahim; Deborah Francis; Kristine R Broglio; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Sonja E Singletary; Kelly K Hunt; Aysegul A Sahin; Francisco Esteva; William F Symmans; Michael S Ewer; Thomas A Buchholz; Gabriel N Hortobagyi Journal: Clin Cancer Res Date: 2007-01-01 Impact factor: 12.531
Authors: Georgiana K Ellis; William E Barlow; Julie R Gralow; Gabriel N Hortobagyi; Christy A Russell; Melanie E Royce; Edith A Perez; Danika Lew; Robert B Livingston Journal: J Clin Oncol Date: 2011-01-10 Impact factor: 44.544
Authors: Harold J Burstein; Jennifer R Bellon; Sharon Galper; Hsiao-Ming Lu; Irene Kuter; Alphonse G Taghian; Julia Wong; Rebecca Gelman; Craig A Bunnell; Leroy M Parker; Judy E Garber; Eric P Winer; Jay R Harris; Simon N Powell Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-21 Impact factor: 7.038
Authors: L Kosma; M Koukourakis; J Skarlatos; C Zambatis; A Ardavanis; K Beroukas; D Yannakakis Journal: Am J Clin Oncol Date: 1997-12 Impact factor: 2.339
Authors: Alba Rodríguez-Martínez; Diego de Miguel-Pérez; Francisco Gabriel Ortega; José Luis García-Puche; Inmaculada Robles-Fernández; José Exposito; Jordi Martorell-Marugan; Pedro Carmona-Sáez; María Del Carmen Garrido-Navas; Christian Rolfo; Hugh Ilyine; José Antonio Lorente; Marta Legueren; María José Serrano Journal: Breast Cancer Res Date: 2019-02-06 Impact factor: 6.466